AlphAIAlphAI — Financial news for AI agents
investing.comOCT 201 min read$RAPP

Guggenheim raises Rapport Therapeutics price target to $70 on trial data

Guggenheim raised its price target on Rapport Therapeutics (RAPP) to $70 from $65, citing positive Phase 2 trial results for bipolar mania. The trial met primary and secondary endpoints, with a 3.1-point placebo-adjusted YMRS reduction. Guggenheim increased its success probability to 65% and adjusted its expected launch to 2030. The stock is currently trading at $30.20, with a Strong Buy consensus among analysts.

Original reporting
investing.com
Published Oct 20, 2026, 6:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 7:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RAPP
Bullish
high confidence
Mentioned
$RAPP
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RAPPBullishMed
01

Why it matters

The data represent a material catalyst, likely driving short‑term buying pressure.

02

Market read

New trial data and analyst upgrades create a clear short‑term upside case for RAPP.

03

What to watch

Potential regulatory delays and competition from other bipolar therapies.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Rapport Therapeutics (NASDAQ:RAPP) announced Phase 2 results for its bipolar mania candidate RAP‑219, prompting several analysts to raise price targets.

Company-level read

Ticker impact

$RAPPBullishHigh confidence
Context

Guggenheim raised its price target to $70 after reporting positive Phase 2 bipolar mania trial results.

Expected impact

likely upward as market prices in the improved outlook

Evidence & confidence

New Phase 2 data and multiple analyst target hikes provide fresh, material information.

Market effects

Sector

Positive data may lift sentiment in the broader neuro‑psychiatric biotech sector.

Regional

U.S. biotech market sees modest boost.

Global

Limited to investors tracking clinical‑trial driven biotech stocks.

Counterpoint

What could challenge this read

Trial endpoints were modest; market may have already priced in optimism.

Key entities

  • Analyst Firm
    Guggenheim

    Raised price target to $70 and increased success probability.

  • Analyst Firm
    Raymond James

    Raised price target to $86.

Read at source← All news

Related articles

OCT 21
$RAPPMed

Jones Trading raises Rapport Therapeutics price target on pipeline potential

Jones Trading raised its price target for Rapport Therapeutics (RAPP) to $82 from $50, maintaining a Buy rating. The firm cited positive clinical trial results for the company’s RAP-219 drug candidate in FOS and BPM indications. The stock currently trades at $29.37, giving the company a market capitalization of $1.41 billion. Analysts have varied price targets and ratings for RAPP, with a consensus Strong Buy rating.

investing.com1 min
OCT 20
$RAPPHigh

RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study

RAPP stock initially rose but later tempered gains due to concerns over higher discontinuation rates in a bipolar mania study. Analysts at H.C. Wainwright and Raymond James raised their price targets to $66 and $86 respectively, while Wells Fargo maintained an Overweight rating with a $51 target. Retail traders on Stocktwits reacted bullishly, with some suggesting the company is a potential buyout candidate. The stock is down 3% year-to-date.

finance.yahoo.com2 min
OCT 20
$RAPPHighAI 8/10

Truist reiterates Rapport Therapeutics stock rating on trial data

Truist Securities reiterated a Buy rating and $56.00 price target for Rapport Therapeutics (RAPP) after positive clinical trial results for RAP-219 in bipolar mania. The stock is currently trading at $29.74, with a Wall Street consensus of Strong Buy and price targets ranging from $50 to $80. Analysts noted consistent efficacy, a clean safety profile, and planned Phase 3 enhancements. The company maintains a strong financial position with a current ratio of 15.72.

investing.com2 min
OCT 20
$RAPPHighAI 8/10

TD Cowen reiterates Buy on Rapport Therapeutics stock after trial

TD Cowen reiterated a Buy rating on Rapport Therapeutics (RAPP) after positive Phase II trial results for RAP-219 in bipolar mania. The trial met primary and secondary endpoints, with a 3.1 point placebo-adjusted improvement on the Young Mania Rating Scale. TD Cowen estimates peak sales of $2.9 billion for RAP-219 and values RAPP at $60 per share, citing strong financial health and pipeline potential.

investing.com2 min
OCT 20
$RAPPMedAI 8/10

BTIG raises Rapport Therapeutics price target to $89 on trial data

BTIG raised its price target for Rapport Therapeutics (NASDAQ:RAPP) to $89 from $75, citing positive clinical trial results for RAP-219 in mania. The stock is currently trading at $30.86. Analysts highlight the drug's efficacy and safety, with Wall Street maintaining a strong buy consensus. Other analysts have also raised price targets, reflecting optimism about RAP-219's potential in treating bipolar mania and epilepsy.

investing.com2 min